NE
Newbury Pharmaceuticals AB (publ)
NEWBRY.ST · STO
2.40 kr -0.41% (-0.01 kr)
1M -13.36%
Market Cap 62.5M kr
P/E Ratio -
Div. Yield -
ROE 52.09%
Piotroski F-Score Weak
1/9Valuation
50 /100
Fair P/B 1.39x
P/S 51.97x
P/FFO N/A
Growth
96 /100
Growing Book val. growth 10.51%
Rev. growth 135.24%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 2,096.34%
Gross margin 345.67%
FCF margin 967.64%
Quality
0 /100
Poor ROA 28.75%
ROIC 46.71%
Asset turnover 0.01x
Debt
58 /100
Moderate Int. coverage -31.75x
Debt/Equity 0.00x
Current ratio 1.21x
Stability
18 /100
Unstable EPS volatility 71.37%
Beta 1.26x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o NEWBRY.ST
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Karl Alexius Tiger Karlsson
Employees
7
Headquarters
Lund